Monday November 26, 2018 0 comments
AURORA -- Machavert Pharmaceuticals, a drug development company focused on bioactive phospholipid therapeutics for the treatment of cancer, recently announced the progress of its MP1000 candidate at the European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association of Cancer Research (AACR) Annual Symposium 2018 in Dublin, Ireland.
"The data presented at EORTC demonstrated MP1000 anti-tumor activity in a diverse range of models including KRAS mutant solid tumors, as well as in liquid tumor models,” said Dr. Neal Goodwin, Machavert’s chief scientific officer.
“KRAS mutant tumors may represent up to 30% of all cancers and offering a unique therapeutic approach will be advantageous to patients that have few precision medicine treatment options for these types of cancers.
"We also observed inhibition of tumor growth in aggressive indolent non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), and multiple myeloma models. Additionally, MP1000 formulated as nanoparticles was successfully shown to deliver a payload test compound to NHL cells and offer increased anti-tumor proliferative activity."
Machavert said the efficacy of MP1000 monotherapy is currently being investigated in human immune system tumor models. The drug candidate is currently entering preclinical IND-enabling studies, a prerequisite for seeking an FDA IND approval for human clinical trial entry, the company said.